Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment
Abstract Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, can be used to treat GCTB. We focused on potential immunotherapy for GCTB...
Main Authors: | Yu Toda, Kenichi Kohashi, Hidetaka Yamamoto, Shin Ishihara, Yoshihiro Ito, Yosuke Susuki, Kengo Kawaguchi, Daisuke Kiyozawa, Dai Takamatsu, Izumi Kinoshita, Yuichi Yamada, Junki Maehara, Atsushi Kimura, Sadafumi Tamiya, Kenichi Taguchi, Tomoya Matsunobu, Yoshihiro Matsumoto, Yasuharu Nakashima, Masaaki Mawatari, Yoshinao Oda |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-94022-w |
Similar Items
-
Aggressive angiomyxoma of the pelvis with a cellular nodule composed of tumor cells showing epithelioid features
by: Shogo Tajima, et al.
Published: (2014-08-01) -
Risk Factors of Periprosthetic Infection in Patients with Tumor Prostheses Following Resection for Musculoskeletal Tumor of the Lower Limb
by: Toshifumi Fujiwara, et al.
Published: (2020-09-01) -
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01) -
Efficiency of denosumab in giant cell tumor of the bone
by: N N Semenov
Published: (2013-06-01) -
THE USE OF DENOSUMAB IN GIANT CELL TUMORS IN THE SACRUM
by: PEDRO LUIS BAZÁN, et al.